Hodgkin Lymphoma Clinical Practice Guidelines (NCCN, 2022)

National Comprehensive Cancer Network

These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

April 29, 2022

Guidelines for the management of Hodgkin lymphoma were published in April 2022 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network (JNCCN).[1]

Radiation therapy (RT) delivery techniques that reduce doses to organs at risk (OARs) in a clinically meaningful manner without compromising target coverage should be considered in patients with Hodgkin lymphoma (HL), especially those with early-stage disease.

Chemotherapy followed by restaging with PET/CT is recommended for patients with stage III–IV classical Hodgkin lymphoma (cHL).

Second-line systemic therapy followed by high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR) with or without RT is recommended for patients with relapsed or refractory (R/R) cHL.

Maintenance therapy with brentuximab vedotin (BV) following HDT/ASCR can be considered for patients at high risk for relapse.

Nivolumab or pembrolizumab (as monotherapy or in combination regimens) are also options for R/R disease in appropriate patients.

Long-term follow-up with careful monitoring for late treatment-related adverse events (trAEs) and counseling about issues of survivorship should be part of the management of patients with HL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.